Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
64.18 USD | -1.68% | -0.58% | -23.39% |
04:51pm | Oppenheimer Adjusts Cytokinetics Price Target to $106 From $107, Maintains Outperform Rating | MT |
May. 08 | Cytokinetics Q1 Net Loss Narrows, Revenue Declines | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.39% | 6.84B | |
+2.73% | 108B | |
+10.07% | 105B | |
+1.57% | 23.46B | |
-11.99% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-6.87% | 17.19B | |
+5.95% | 13.99B | |
+36.05% | 12.53B |
- Stock Market
- Equities
- CYTK Stock
- News Cytokinetics, Incorporated
- JPMorgan Starts Cytokinetics at Overweight With $58 Price Target